Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(145 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(170 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(86 products)
- Src(78 products)
- Syk(38 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1414 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
MAX-40279
CAS:<p>MAX-40279 is a potent, dual FLT3 kinase and FGFR kinase inhibitor. MAX-40279 has potential for acute myeloid leukemia (AML) studies.</p>Formula:C22H23FN6OSColor and Shape:SolidMolecular weight:438.52EGFR/HER2/TS-IN-1
CAS:<p>EGFR/HER2/TS-IN-1 inhibits EGFR (0.203 μM), HER2 (0.088 μM), TS (0.168 μM), and induces apoptosis in MCF7 cells.</p>Formula:C24H15N5O4S2Color and Shape:SolidMolecular weight:501.54LDC0496
CAS:<p>LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.</p>Formula:C32H35N5O3Color and Shape:SolidMolecular weight:537.65AFG210
CAS:<p>AFG210 is a novel first-generation “type II” FLT3 inhibitor.</p>Formula:C19H14F3N3O2Color and Shape:SolidMolecular weight:373.33VEGFR-2-IN-23
CAS:<p>VEGFR-2-IN-23 (11b) is a potent VEGFR-2 inhibitor with an IC50 of 0.34 nM, exhibits antitumor effects, and causes G1 cell cycle arrest.</p>Formula:C22H15N5O2Color and Shape:SolidMolecular weight:381.39Lck-IN-1
CAS:<p>Lck-IN-1 is a potent inhibitor of lymphocyte protein tyrosine kinase (Lck) [1].</p>Formula:C14H15N5Color and Shape:SolidMolecular weight:253.3AGL 2043
CAS:<p>AGL 2043 is a potent, reversible, ATP-competitive inhibitor of type III receptor tyrosine kinases.</p>Formula:C15H12N4SColor and Shape:SolidMolecular weight:280.35α7 nAchR-JAK2-STAT3 agonist 1
CAS:<p>α7 nAchR-JAK2-STAT3 agonist 1 is a potent inhibitor of the α7 nAchR-JAK2-STAT3 pathway that acts on nitric oxide (NO) (IC50: 0.32 μM).</p>Formula:C25H30O6Color and Shape:SolidMolecular weight:426.5BCR-ABL-IN-5
CAS:<p>BCR-ABL-IN-5: Bcr-Abl kinase inhibitor, IC50: Bcr-AblWT 0.014 μM, Bcr-AblT315I 0.45 μM; anti-leukemia cell growth.</p>Formula:C25H21Cl2N5O2Color and Shape:SolidMolecular weight:494.37Luxeptinib
CAS:<p>Luxeptinib (CG-806) is an oral, non-covalent pan-FLT3/BTK inhibitor for acute myeloid leukemia.</p>Formula:C25H17F4N5O2Color and Shape:SolidMolecular weight:495.43GDC-4379
CAS:<p>GDC-4379 is a JAK1 inhibitor that can be used to study asthma.</p>Formula:C21H18ClF2N7O3Color and Shape:SolidMolecular weight:489.86PHA-680626
CAS:<p>PHA-680626 is a PLK inhibitor, effective on resistant leukemia cells, with IC50: Plk1 (0.53 μM), Plk2 (0.07 μM), Plk3 (1.61 μM).</p>Formula:C23H26N6O2SColor and Shape:SolidMolecular weight:450.56EGFR-IN-63
CAS:<p>EGFR- IN-63 is an EGFR inhibitor with an IC50 value of 0.096 μM. EGFR- IN-63 exhibited anticancer effects on MCF-7 cells (IC50: 2.49 μM).</p>Formula:C20H12BrN5SColor and Shape:SolidMolecular weight:434.31BTK-IN-22
CAS:<p>BTK-IN-22 is a selective BTK inhibitor with IC50 of 0.9 nM; also targets BLX, BMX (IC50s: 1.4, 1.2 nM); better selectivity than Ibrutinib.</p>Formula:C26H26N6O2Color and Shape:SolidMolecular weight:454.52pan-HER-IN-2
CAS:<p>pan-HER-IN-2 (Compound C6) is an orally active, reversible, broad-spectrum HER inhibitor that acts on EGFR (IC50: 0.72 nM), HER4 (IC50: 2.0 nM), EGFRT790M (IC50</p>Formula:C19H15BrClN5OColor and Shape:SolidMolecular weight:444.71EGFR/C797S-IN-1
CAS:<p>EGFR/C797S-IN-1: Potent EGFR-C797S inhibitor, IC50 of 0.128 µM, dose-dependent p-EGFR suppression, anti-tumor properties.</p>Formula:C28H30N4O3Color and Shape:SolidMolecular weight:470.56PDGFRα/FLT3-ITD-IN-3
CAS:<p>PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of PDGFRα (IC50: 0.153 μM), FLT3 (IC50: 0.004 μM) and PDGFRα/FLT3-ITD-IN-3 has the potential to be</p>Formula:C26H39N9Color and Shape:SolidMolecular weight:477.65CHMFL-ABL-053
CAS:<p>CHMFL-ABL-053: potent, selective BCR-ABL/SRC/p38 inhibitor (IC50: 70/90/62 nM). Orally available, potential CML drug.</p>Formula:C28H26F3N7O2Color and Shape:SolidMolecular weight:549.55EGFR/HER2-IN-9
CAS:<p>EGFR/HER2-IN-9, a compound inhibiting both EGFR and HER2, demonstrates potency with IC50 values of 3.2 nM for EGFR, 14 nM for HER2, and 8.3 nM against the EGFR</p>Formula:C25H25ClFN5O4Color and Shape:SolidMolecular weight:513.95Ebselen oxide
CAS:<p>Ebselen oxide (EB-2) is a HER2 inhibitor with antibacterial and antifungal activity and has shown cytoprotective effects against HN2 in vitro.</p>Formula:C13H9NO2SePurity:98%Color and Shape:SolidMolecular weight:290.18SMU-B
CAS:<p>SMU-B is a well-tolerated c-Met/ALK dual inhibitor.</p>Formula:C26H25Cl2FN4O2Purity:98%Color and Shape:SolidMolecular weight:515.41BTK-IN-23
CAS:<p>BTK-IN-23: BTK inhibitor, IC50=12.8 nM; also blocks BLX (35.6 nM), BMX (5.7 nM); better selectivity than Ibrutinib.</p>Formula:C27H28N6O2Color and Shape:SolidMolecular weight:468.55EGFR/CDK2-IN-1
CAS:<p>EGFR/CDK2-IN-1, an inhibitor of both EGFR and CDK2, demonstrates effective cytotoxicity towards MCF7 and HepG2 cells, suggesting its potential application in</p>Formula:C19H12BrClO2Color and Shape:SolidMolecular weight:387.65Ficonalkib
CAS:<p>Ficonalkib is a potent antineoplastic agent that inhibits the Anaplastic Lymphoma Kinase (ALK) tyrosine kinase receptor.</p>Formula:C29H39N7O3SColor and Shape:SolidMolecular weight:565.73PHM16
CAS:<p>PHM16 is an ATP competitive FAK and FGFR2 inhibitor.</p>Formula:C20H22N6O4Purity:98%Color and Shape:SolidMolecular weight:410.43BI-1622
CAS:<p>BI-1622, an oral HER2 inhibitor, IC50: 7 nM, >25x selectivity over EGFR, shows effective in vivo antitumor activity.</p>Formula:C26H24N10O2Color and Shape:SolidMolecular weight:508.53ProMMP-9 inhibitor-3c
CAS:<p>ProMMP-9 inhibitor-3c hinders MMP-9 homodimers, blocks proMMP-9/α4β1 integrin/CD44 binding, and detaches EGFR.</p>Formula:C18H20FN3O2SColor and Shape:SolidMolecular weight:361.43EGFR-IN-57
CAS:<p>EGFR-IN-57: potent EGFR-TK blocker, IC50 0.054 μM, oral. Halts VEGFR-2, CK2α, topo IIβ, tubulin. Causes G2/M, pre-G1 arrest, cancer cell death.</p>Formula:C22H15N3O2SColor and Shape:SolidMolecular weight:385.44CPL304110
CAS:<p>CPL304110: oral, selective FGFR 1-3 inhibitor; IC50 - FGFR1: 0.75nM, FGFR2: 0.5nM, FGFR3: 3.05nM.</p>Formula:C25H30N6O2Color and Shape:SolidMolecular weight:446.54EGFR/HER2/CDK9-IN-3
CAS:<p>EGFR/HER2/CDK9-IN-3 inhibits EGFR (191.08 nM IC50), HER2 (132.65 nM), CDK9 (113.98 nM); shows anti-tumor effects.</p>Formula:C24H21N3O4S2Color and Shape:SolidMolecular weight:479.57EGFR-IN-52
CAS:<p>EGFR-IN-52, a potent EGFR inhibitor, has IC50s: 0.358 μM (wild-type), 86.02 μM (L858R-TK), 432.67 μM (T790M-TK); induces cancer cell apoptosis.</p>Formula:C19H18N4O3SColor and Shape:SolidMolecular weight:382.44UNC-CA359
CAS:<p>UNC-CA359: potent EGFR inhibitor, IC50=18 nM, strong anti-tumor effect, promising for chordoma.</p>Formula:C18H14ClN3O2Color and Shape:SolidMolecular weight:339.78NSC 33994
CAS:<p>NSC 33994 is a selective inhibitor of JAK2 (IC50 = 60 nM). It also shows no effect on Src and TYK2 tyrosine kinase activity at a concentration of 25 μM.</p>Formula:C28H42N2O2Purity:98%Color and Shape:SolidMolecular weight:438.65JAK3/BTK-IN-6
CAS:<p>JAK3/BTK-IN-6: potent BTK (0.6 nM) & JAK3 (0.4 nM) inhibitor, stable in human liver, for blood/immune research.</p>Formula:C21H17BF3N5O3Color and Shape:SolidMolecular weight:455.2EGFR-IN-21
CAS:<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Formula:C36H44BrN10O2PColor and Shape:SolidMolecular weight:759.68BCR-ABL-IN-6
CAS:<p>BCR-ABL-IN-6, an imatinib derivative, inhibits Bcr-AblWT (4.6 nM IC50) and T315I (277 nM), for chronic myeloid leukemia study.</p>Formula:C27H22F3N5O2Color and Shape:SolidMolecular weight:505.49VS 8
CAS:<p>VS 8: potent oral VEGFR-2 inhibitor, anti-angiogenic, induces cancer cell apoptosis & migration, acts on CSCs.</p>Formula:C26H20F3N3O3Color and Shape:SolidMolecular weight:479.45EGFR/HER2-IN-2
CAS:<p>EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).</p>Formula:C26H23N5O3Color and Shape:SolidMolecular weight:453.49JBJ-09-063 hydrochloride
<p>JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.</p>Formula:C31H30ClFN4O3SColor and Shape:SolidMolecular weight:593.11EGFR-IN-25
CAS:<p>EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.</p>Formula:C34H43N9O2Color and Shape:SolidMolecular weight:609.76EGFR-IN-54
CAS:<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Formula:C17H14N4O4S3Color and Shape:SolidMolecular weight:434.51NSC114792
CAS:<p>NSC114792 is a selective JAK3 inhibitor.</p>Formula:C26H32N4O2SPurity:98%Color and Shape:SolidMolecular weight:464.62SUN13837
CAS:<p>SUN13837, an oral FGFR modulator, crosses the BBB and shows neuroprotective promise.</p>Formula:C21H29N5O2Color and Shape:SolidMolecular weight:383.49TYK2-IN-11
CAS:<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>Formula:C18H17N5O3SColor and Shape:SolidMolecular weight:383.42EGFR/HER2-IN-3
CAS:<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Formula:C26H23N5O3Color and Shape:SolidMolecular weight:453.49FLT3-IN-18
CAS:<p>FLT3-IN-18: potent, selective FLT3 inhibitor, IC50 0.003 μM, induces apoptosis, G1 arrest, blocks FLT3/STAT5, potential in AML research.</p>Formula:C26H36N8OColor and Shape:SolidMolecular weight:476.62(R)-Elsubrutinib
CAS:<p>(R)-Elsubrutinib ((R)-ABBV-105), a Btk inhibitor, is used in research on immune diseases and cancer.</p>Formula:C17H19N3O2Color and Shape:SolidMolecular weight:297.35EGFR-IN-69
CAS:<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Formula:C31H37Cl2N7O3SColor and Shape:SolidMolecular weight:658.64VEGFR2 Kinase Inhibitor II
CAS:<p>VEGFR2 kinase inhibitor II: Reversible, cell-permeable, targets VEGFR2 (IC50=70nM), less effective on PDGFRβ (IC50=920nM). Blocks VEGF/PDGF-stimulated growth.</p>Formula:C17H15BrN2OColor and Shape:SolidMolecular weight:343.22BLK-IN-1
CAS:<p>BLK-IN-1 selectively blocks BLK and BTK with IC50s of 18.8 and 20.5 nM, used in cancer research.</p>Formula:C29H23F3N6O3Color and Shape:SolidMolecular weight:560.53
